Genexine Co., Ltd. (095700)

Overview

Genexine, Inc., operating both domestically in South Korea and on an international stage, positions itself as a leading biotechnology enterprise specializing in innovative immunotherapies. Launched in 1999 and undergoing a name change from Genexine Co., Ltd. to Genexine, Inc. in March 2013, the company has carved a niche in the biotech industry with its focus on revolutionary medical solutions. Utilizing its proprietary hybrid Fc platform and DNA vaccine technology, Genexine seeks to address a host of serious health challenges by enhancing the efficacy and duration of protein drugs and eliciting robust immune responses against viral infections and cancer. Through its ambitious research and development efforts, Genexine is pioneering treatments across various stages of clinical trials, targeting a wide spectrum of diseases including growth hormone deficiency, anemia, neutropenia, solid tumors, lymphopenia, COVID-19, autoimmune diseases, transplantation, diabetes, cervical cancer, and head and neck cancer. Positioned at the cutting edge of biotechnology, Genexine's commitment to innovation is driving progress in the treatment of complex medical conditions around the world.

Products and Services

• GX-H9: Currently in Phase II and III clinical trials, GX-H9 is at the forefront of Genexine's offerings for treating both adult and pediatric growth hormone deficiency. This therapeutic candidate exemplifies the company's commitment to addressing endocrine disorders with innovative solutions.
• GX-E4: Targeting the treatment of anemia, GX-E4 is undergoing Phase III clinical trials. This product highlights Genexine’s effort in combating blood conditions through advanced biotechnological research.
• GX-G3: In Phase II clinical trials, GX-G3 is a therapeutic candidate aimed at treating neutropenia. This development underscores Genexine’s dedication to enhancing immune system function and combating infections.
• GX-I7: A versatile candidate, GX-I7, is navigating through Phase I and II clinical trials for the treatment of solid tumors, lymphopenia, and COVID-19. This initiative reflects Genexine's comprehensive approach to tackling infectious diseases and cancer.
• GX-P1: Focused on autoimmune diseases and transplantation, GX-P1 is in Phase I clinical trials. It represents Genexine's commitment to immunological innovation, aiming to redefine treatment paradigms in areas of unmet medical need.
• GX-G6: With its engagement in Phase II clinical trials for the treatment of diabetes, GX-G6 showcases Genexine’s venture into metabolic disorders, aiming to improve the lives of those affected by diabetes through novel therapeutic approaches.
• GX-188E: Dedicated to addressing cancer, GX-188E is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. This candidate emphasizes Genexine’s leadership in developing targeted cancer therapies, providing hope for better and more effective treatments.